MK-0616, an experimental oral medication aimed at reducing LDL cholesterol, is intended to be the first oral PCSK9 inhibitor.

Merck's heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other ...

Following a pre-Congress press briefing and data presented onsite at ASCO 2025 itself, pharmaphorum spoke with Dr Victoria ...

Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

A new slate of vaccine advisers to the US Centers for Disease Control and Prevention voted Thursday to recommend that ...

The votes in favor of Merck's shot are a sigh of relief after Kennedy gutted the panel and tapped replacements, some of whom ...

Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's ...

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

The recommendation for Enflonsia is indicated for respiratory syncytial virus prevention in infants under eight months of age, expanding protection options ahead of the 2025–2026 season.

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

Robert F. Kennedy Jr.’s vaccine advisory committee recommended Merck & Co.’s shot to prevent newborns from getting RSV, ...